Bubs Australia (BUB) Q1 2027 TU earnings summary

Executive summary

• Q1 FY27 net revenue was $23.1m, down 9.8% YoY; trading improved through the quarter after a slower July as regulatory-reset impacts eased.

• Permanent FDA authorisation for three infant formula products and distribution in 12,000+ US stores support further growth; US retail scan sales rose 46.5% YoY and 10.6% QoQ.

Financial highlights

• Group net revenue was $23.1m versus $25.6m in Q1 FY26; US translation reduced reported revenue by $1.2m, with exchange rates of $0.71 versus $0.65.

• Operating cash outflow was $6.006m versus $4.4m in Q1 FY26; receipts from customers were $24.193m.

• Cash and cash equivalents were $6.376m at quarter-end; total available liquidity, including $7.0m of undrawn facilities, was $13.376m.

Outlook and guidance

• Targeted marketing investment is intended to build awareness and convert consumer interest into sales, particularly in the US; inventory was built to support growth.

• China channel sell-in and sell-through normalised, with modest revenue growth; Australia showed early signs of stabilising and Rest of World trading was recovering.

• Initial resupply shipment to Vietnam supported the brand relaunch; work continued toward re-entry into remaining affected markets, including Singapore.